Key Highlights

Risk & Performance

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Phase 3

3(75.0%)

Phase 2

1(25.0%)

4Total

Phase 3(3)

Phase 2(1)

Loading network data...

Showing 4 of 4 trials

Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma

Role: collaborator

Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Role: collaborator

Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

Role: collaborator

Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation

Role: collaborator

All 4 trials loaded